SCHEMBL30910085

SCHEMBL30910085

CC(C(=O)N1CCN(c2ccc(Cl)cc2)c2ccccc21)N1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 1/20 0.51
▸ GAA P10253 2/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ LMNA P02545 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CHRNA1 P02708 1/20 0.41
▸ CHRNG P07510 1/20 0.41
▸ CHRNB1 P11230 1/20 0.41
▸ CHRNB2 P17787 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ CHRNB4 P30926 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ CHRNA3 P32297 1/20 0.41
▸ CHRNA4 P43681 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ CHRND Q07001 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26092223 1.00 DRD4 (0.51) DRD4GAAKMT2AMEN1LMNA
SCHEMBL26092095 0.99 DRD4 (0.50) DRD4GAAKMT2AMEN1LMNA
SCHEMBL30379078 0.99 DRD4 (0.50) DRD4GAAKMT2AMEN1LMNA
SCHEMBL30378570 0.91 DRD4 (0.54) DRD4GAAKMT2AMEN1LMNA
SCHEMBL26088333 0.91 DRD4 (0.54) DRD4GAAKMT2AMEN1LMNA
SCHEMBL26092208 0.90 GAA (0.47) DRD4GAAKMT2AMEN1LMNA
SCHEMBL30379742 0.90 GAA (0.47) DRD4GAAKMT2AMEN1LMNA
SCHEMBL26088160 0.89 GAA (0.46) DRD4GAAKMT2AMEN1LMNA
SCHEMBL30910050 0.89 GAA (0.46) DRD4GAAKMT2AMEN1LMNA
SCHEMBL30910083 0.88 CHRNA1 (0.51) DRD4GAAKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US claimed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP claimed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 DRD4 3728/4885GAA 1343/4885KMT2A 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback